Compare FIP & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIP | LXRX |
|---|---|---|
| Founded | 2021 | 1995 |
| Country | United States | United States |
| Employees | 1110 | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.0M | 660.9M |
| IPO Year | 2021 | 2000 |
| Metric | FIP | LXRX |
|---|---|---|
| Price | $5.83 | $1.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $11.00 | $4.15 |
| AVG Volume (30 Days) | 840.3K | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | 16.91 | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $502,520,000.00 | $49,803,000.00 |
| Revenue This Year | $58.19 | N/A |
| Revenue Next Year | $30.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 51.59 | ★ 60.24 |
| 52 Week Low | $3.43 | $0.49 |
| 52 Week High | $7.93 | $1.84 |
| Indicator | FIP | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.91 | 64.34 |
| Support Level | $4.53 | $1.07 |
| Resistance Level | $6.25 | N/A |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 93.28 | 98.61 |
FTAI Infrastructure Inc is engaged in five segments; Railroad segment, which includes eight freight railroads and one switching company that provide rail service to certain manufacturing and production facilities; the Jefferson Terminal segment, which consists of a multi-modal crude oil and refined products terminal and other related assets; The Repauno segment, which consists of a deep-water port located along the Delaware River with an underground storage cavern, a multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities; Power and Gas segment, which comprised Long Ridge, a multi-modal terminal located along the Ohio River; and Sustainability and Energy Transition segment, which comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.